검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Adalimumab treatment arm |
Overview Company | AbbVie |
Overview Modality | ANTIBODY |
Overview Target | Psoriasis |
Overview Indication | Psoriasis; Cardiovascular Diseases |
Overview Phase | APPROVED |
Overview Status | ACTIVE |
MoA Mechanism | targeted disruption of the physiological pathway |
MoA Biomarker | biomarker-stratified multicentre randomised controlled trial, which the baseline proportion of CD4+T cells wi |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis.. ABP 501, now approved as AMJEVITA ® (adalimumab-atto, USA)/AMGEVITA ® (adalimumab, EU), is a biosimilar to adalimumab reference product (RP, Humira ® ) indicated for the treatment of various chronic inflammatory con… |
Clinical Primary efficacy | ORR 2% |
Clinical ORR | 2% |
Clinical Result source | ClinicalTrials.gov NCT00808509 |
Clinical Data Tier / Score | A · 40 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Adalimumab treatment arm |
Overview Company | AbbVie |
Overview Modality | ANTIBODY |
Overview Target | Psoriasis |
Overview Indication | Psoriasis; Cardiovascular Diseases |
Overview Phase | APPROVED |
Overview Status | ACTIVE |
MoA Mechanism | targeted disruption of the physiological pathway |
MoA Biomarker | biomarker-stratified multicentre randomised controlled trial, which the baseline proportion of CD4+T cells wi |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis.. ABP 501, now approved as AMJEVITA ® (adalimumab-atto, USA)/AMGEVITA ® (adalimumab, EU), is a biosimilar to adalimumab reference product (RP, Humira ® ) indicated for the treatment of various chronic inflammatory con… |
Clinical Primary efficacy | ORR 2% |
Clinical ORR | 2% |
Clinical Result source | ClinicalTrials.gov NCT00808509 |
Clinical Data Tier / Score | A · 40 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교